InnoCare Pharma Limited (INCPF PINK) stock market data APIs
$1.5436
0(0%)
as of September 25, 2026
Try our APIs with
free plan!
InnoCare Pharma Limited Financial Data Overview
Price chart is built with
Anychart
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. The company has research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Prev. Close
1.5436
Open
1.5436
High
1.5436
Low
1.5436
52 wk Range
1.55-3.26
Market Cap
2 739 M
P/E Ratio
25.8333
Shares Outstanding
1 494 M
Revenue
2 781 M
EPS
0.0117
Beta
0.39
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get InnoCare Pharma Limited data using free add-ons & libraries
Get InnoCare Pharma Limited Fundamental Data
InnoCare Pharma Limited Fundamental data includes:
- Net Revenue: 2 781 M
- EBITDA: 779 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-20
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
InnoCare Pharma Limited News
New
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Centene in focus
Wall Street closed higher Friday as easing Treasury yields and lower oil prices supported equities, with investors continuing to monitor developments surrounding the Strait of Hormuz. The blue-chip D...
InnoCare inks licensing deal with Eli Lilly worth up to $3.35B
[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage * InnoCare Pharma (INCPF [https://seekingalpha.com/symbol/INCPF]) has entered a research collabor...
InnoCare's Zurletrectinib Gets Priority Review By NMPA For Pediatric Solid Tumours In China
(RTTNews) - InnoCare Pharma Ltd (9969.HK), a commercial-stage biopharmaceutical company, announced that the Centre for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA...
Asian Market Highlights: Q & M Dental Group (Singapore) Among 3 Stocks That May Be Trading Below Their Estimated Value
As global markets grapple with concerns over AI disruption and mixed economic signals, Asian stocks have shown resilience, with some indices like Japan's Nikkei 225 experiencing notable gains. In this...
Get InnoCare Pharma Limited fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
